...
机译:遗传基础对黑色素瘤CTLA-4阻断的临床反应
Department of Medicine Columbia UniversityNew York United States Human Oncology and Pathogenesis;
Human Oncology and Pathogenesis Program Columbia University Memorial Sloan Kettering Cancer;
Department of Medicine Columbia UniversityNew York United States Swim Across America-Ludwig;
Immunology Program Ludwig Center for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center;
Department of Molecular and Medical Pharmacology University of California Los AngelesLos Angeles;
Human Oncology and Pathogenesis Program Columbia University Memorial Sloan Kettering Cancer;
Human Oncology and Pathogenesis Program Columbia University Memorial Sloan Kettering Cancer;
Department of Medicine Columbia UniversityNew York United States Weill Cornell Medical College;
Immunology Program Ludwig Center for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center;
Immunology Program Ludwig Center for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center;
Department of Pathology Columbia UniversityNew York United States;
Department of Mathematics Columbia UniversityNew York United States;
Human Oncology and Pathogenesis Program Columbia University Memorial Sloan Kettering Cancer;
Swim Across America-Ludwig Collaborative Research Laboratory Columbia UniversityNew York United;
Swim Across America-Ludwig Collaborative Research Laboratory Columbia UniversityNew York United;
Swim Across America-Ludwig Collaborative Research Laboratory Columbia UniversityNew York United;
Bristol-Myers SquibbPrinceton NJ United States;
Bristol-Myers SquibbPrinceton NJ United States;
Department of Molecular and Medical Pharmacology University of California Los AngelesLos Angeles;
Department of Medicine Columbia UniversityNew York United States Swim Across America-Ludwig;
Human Oncology and Pathogenesis Program Columbia University Memorial Sloan Kettering Cancer;
机译:遗传基础对黑素瘤CTLA-4阻断的临床反应(Vol 371,PG 2189,2014)
机译:更正:黑色素瘤对CTLA-4阻断的临床反应的遗传基础
机译:遗传基础对黑色素瘤CTLA-4阻断的临床反应
机译:黑色素瘤的免疫应答与脱毛阳岩GD3疫苗接种:1期临床试验
机译:克服黑色素瘤的免疫耐受性:非特异性CTLA-4阻断/干扰素-α和抗原特异性免疫,TLR-9刺激/局部GM-CSF作为黑色素瘤免疫治疗策略的组成部分和相关的治疗有益生物标志物。
机译:黑色素瘤对CTLA-4阻滞的临床反应的遗传基础
机译:遗传基础对黑色素瘤CTLA-4阻断的临床反应